CIK 0001620463 · Non-accelerated filer<br>Smaller reporting company
LeonaBio, Inc.
Sign in to watch- Ticker
- LONA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 453368487
- Phone
- (425) 620-8501
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Former names
- Athira Pharma, Inc., M3 Biotechnology, Inc.
- Open-market buys, last 90 days
- $9,919,161,281
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 85 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-09 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2026-04-09 | San Martin Javier CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +350,000 | 350,000 | ||
| 2026-04-09 | Kosacz Barbara Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-09 | Romano Kelly A Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-09 | Panzara Michael A. Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-09 | Litton Mark James PRESIDENT and CEO | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2026-04-09 | PICKERING GRANT Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-09 | JOHNSON JAMES A Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-09 | FLUKE JOHN M JR Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-09 | EDELMAN JOSEPH Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-03-04 | Renninger Robert CHIEF FINANCIAL OFFICER | Sale | −906 | $5.37 | $5K | 15,851 |
| 2026-03-04 | Worthington Mark GENERAL COUNSEL and CCO | Sale | −1,328 | $5.37 | $7K | 18,376 |
| 2026-03-04 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Sale | −1,359 | $5.37 | $7K | 25,178 |
| 2026-03-04 | San Martin Javier CHIEF MEDICAL OFFICER | Sale | −1,720 | $5.37 | $9K | 15,887 |
| 2026-03-04 | Litton Mark James PRESIDENT and CEO | Sale | −5,156 | $5.37 | $28K | 57,926 |
| 2026-03-03 | Renninger Robert CHIEF FINANCIAL OFFICER | Option exercise | +3,900 | 16,757 | ||
| 2026-03-03 | Renninger Robert CHIEF FINANCIAL OFFICER | Option exercise · Restricted Stock Units | −3,900 | 0 | ||
| 2026-03-03 | Worthington Mark GENERAL COUNSEL and CCO | Option exercise | +5,726 | 19,704 | ||
| 2026-03-03 | Worthington Mark GENERAL COUNSEL and CCO | Option exercise · Restricted Stock Units | −5,726 | 0 | ||
| 2026-03-03 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Option exercise | +5,856 | 26,537 |
Page 2 of 10 · 187 trades